Zubillaga M B, Boccio J R, Nicolini J O, Ughetti R, Lanari E, Caro R A
Radioisotope Laboratory, Facultad de Farmacia y Bioquimica, Buenos Aires, Argentina.
Nucl Med Biol. 1997 Aug;24(6):559-64. doi: 10.1016/s0969-8051(97)00070-x.
To evaluate the effectiveness of a single intratumoral dose of Pirocarbotrat, a gelatin-protected charcoal suspension labeled with chromic [32P]pyrophosphate, studies of bioelimination, biodistribution and therapeutic action were carried out in rats, and the results obtained were compared with those of other 32P dispersions. We found that 78.3% of the treated tumors reduced size after 32 days of treatment. At that time, the total eliminated activity was 12.70 +/- 3.90% distributed in urine (8.30 +/- 1.80%) and feces (4.40 +/- 3.50%). Biodistribution studies demonstrate that 84.50 +/- 2.60% of the injected activity remained in the tumor, with no significant concentration in the rest of the organism. We conclude that Pirocarbotrat can be used as a safe agent for brachytherapy of solid tumors with beta particles.
